HB 797 revises Missouri pharmacy law to expressly include the dispensing of self-administered hormonal contraceptives within the “practice of pharmacy.” It repeals the existing section 338.010 and replaces it with new provisions that define pharmacy practice, preserve existing pharmacist authority over prescriptions, vaccines, nicotine replacement therapy, HIV post-exposure prophylaxis, and medication therapy services, and add a new section authorizing pharmacists to dispense self-administered hormonal contraceptives under a prescription order for medication therapy services.
The bill also creates a new framework in section 338.720 for pharmacist dispensing of hormonal contraceptives. It defines “self-administered hormonal contraceptive,” states that such products may be dispensed without an expiration date on the prescription order, and requires joint rulemaking by the Board of Pharmacy and the Board of Registration for the Healing Arts. Those rules must require pharmacist training, use of a self-screening risk assessment tool, annual verbal referral to a healthcare provider, written records for the patient, and prompt dispensing. The bill further preserves existing insurance coverage laws for contraceptive drugs, devices, products, and services as applied to these pharmacist-dispensed contraceptives.
In addition to the contraceptive provisions, the bill updates and restates pharmacist authority over medication therapy services, including protocols with physicians, and retains limits that pharmacists may not independently diagnose, prescribe, or substitute therapeutics unless authorized. It also continues existing provisions on pharmacist-administered vaccines, including training, observation, emergency protocols, and reporting to the Show Me Vax system, while allowing vaccine administration during declared public health emergencies.
The bill’s impact on state law would be to expand pharmacist scope of practice and create a specific statutory pathway for pharmacy access to hormonal contraception in Missouri. It would affect the Board of Pharmacy, the Board of Registration for the Healing Arts, pharmacists, physicians, insurers, and patients seeking contraceptive access, while also reinforcing regulatory oversight through joint rulemaking and patient-safety requirements.
Because no committee transcript or vote record is provided, there is no documented floor or committee sentiment in the materials. Based on the bill text and caption, the measure appears aimed at increasing access to contraception through pharmacies while maintaining medical oversight and insurance coverage protections. The main likely point of contention is the balance between expanded pharmacist access and concerns about clinical screening, physician involvement, and the scope of pharmacy practice.
HB 797 would amend Missouri pharmacy statutes by repealing section 338.010 and enacting new sections 338.010 and 338.720. The bill would add self-administered hormonal contraceptives to the list of services included in the practice of pharmacy and authorize pharmacists to dispense them under prescribed protocols. It would also require joint rulemaking by the pharmacy and healing arts boards, impose training and counseling requirements, and preserve existing insurance coverage rules for contraceptive products. The bill would affect pharmacists, physicians, patients, insurers, and state licensing boards by formalizing a pharmacy-based access pathway for hormonal contraception.
No committee discussion or vote history is included, so there is no direct record of support or opposition in the provided materials. The bill’s caption and structure suggest a policy goal of expanding access to contraceptives through pharmacists, while keeping safety and oversight measures in place. Overall, the measure appears generally pro-access and regulatory rather than restrictive, with an emphasis on patient safeguards and professional standards.
The principal policy tension is between broader contraceptive access through pharmacies and the extent of pharmacist authority versus physician oversight. Supporters would likely favor easier access, convenience, and expanded reproductive healthcare options, while opponents may focus on whether pharmacists should dispense hormonal contraceptives without a traditional physician visit, the adequacy of required screening and referral procedures, and whether the bill appropriately limits independent prescribing. The bill also preserves joint board rulemaking, which may be a point of contention if stakeholders disagree over how much discretion regulators should have in setting protocols.